

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**RemeGen Co., Ltd.\***

**榮昌生物製藥(煙台)股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 9995)**

## **DISCLOSEABLE TRANSACTION PURCHASE OF WEALTH MANAGEMENT PRODUCTS**

### **PURCHASE OF WEALTH MANAGEMENT PRODUCTS**

At the 36th meeting held by the second session of the Board of the Company on March 27, 2026, a resolution regarding cash management using self-owned funds was considered and approved, pursuant to which the Company may purchase wealth management products using part of idle self-owned funds of not more than RMB2,500.0 million.

The Board announces that, on May 14, 2026, the Company entered into (1) the HTSC Wealth Management Product Agreement No. 1 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB60.0 million from HTSC using idle self-owned funds; (2) the HTSC Wealth Management Product Agreement No. 2 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB75.0 million from HTSC using idle self-owned funds; (3) the HTSC Wealth Management Product Agreement No. 3 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB102.0 million from HTSC using idle self-owned funds; and (4) the HTSC Wealth Management Product Agreement No. 4 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB216.0 million from HTSC using idle self-owned funds.

### **LISTING RULES IMPLICATIONS**

As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in respect of the HTSC Wealth Management Product Agreements (calculated on an aggregation basis) exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of wealth management products under the HTSC Wealth Management Product Agreements therefore constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the reporting and announcement requirements under the Listing Rules.

## BACKGROUND

The Board announces that, on May 14, 2026, the Company entered into (1) the HTSC Wealth Management Product Agreement No. 1 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB60.0 million from HTSC using idle self-owned funds; (2) the HTSC Wealth Management Product Agreement No. 2 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB75.0 million from HTSC using idle self-owned funds; (3) the HTSC Wealth Management Product Agreement No. 3 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB102.0 million from HTSC using idle self-owned funds; and (4) the HTSC Wealth Management Product Agreement No. 4 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB216.0 million from HTSC using idle self-owned funds.

## HTSC WEALTH MANAGEMENT PRODUCT AGREEMENTS

The principal terms of the HTSC Wealth Management Product Agreement No. 1 are set out as follows:

Name of product	:	Guoshou Asset – Yuanliu 2158 Insurance Asset Management Product (國壽資產 – 源流 2158 保險資產管理產品)
Type of product	:	Fixed-income
Risk rating of product	:	Low-to-medium risk
Principal amount	:	RMB60.0 million
Product subscription date	:	May 14, 2026
Product investment period	:	No fixed term. The actual investment period is subject to the redemption date of the subscriber.
Expected annualized yield rate	:	The performance will fluctuate with the market and is subject to uncertainty.
Investment scope	:	The proceeds raised under the product will be invested in debt assets.

The principal terms of the HTSC Wealth Management Product Agreement No. 2 are set out as follows:

Name of product	:	Huatai Zijin Weekly Subscription 6-Month Rolling Hold Bond Initiation Securities Investment Fund (華泰紫金周周購 6 個月滾動持有債券型發起式證券投資基金)
Type of product	:	Fixed-income
Risk rating of product	:	Low-to-medium risk
Principal amount	:	RMB75.0 million
Product subscription date	:	May 14, 2026
Product investment period	:	No fixed term. The actual investment period is subject to the redemption date of the subscriber.
Expected annualized yield rate	:	The performance will fluctuate with the market and is subject to uncertainty.
Investment scope	:	The product's investment scope covers liquid financial instruments, including bonds lawfully issued within China (government bonds, central bank bills, financial bonds, corporate bonds, enterprise bonds, medium-term notes, short-term notes, ultra-short-term notes, publicly issued subordinated bonds, government agency bonds, local government bonds, exchangeable bonds, convertible bonds (including the straight bond portion of convertible bonds with detachable warrants)), asset-backed securities, bond repurchase agreements, bank deposits (including negotiated deposits, time deposits and other bank deposits), negotiable certificates of deposit, money market instruments, treasury bond futures, stocks (including those listed on the Main Board, ChiNext and other stocks approved or registered by the CSRC), and other financial instruments permitted by applicable laws and regulations or the CSRC.

The principal terms of the HTSC Wealth Management Product Agreement No. 3 are set out as follows:

Name of product	:	Shengxinxiang – Huatai WEFUND Fixed Income Private FOF 1066 Separate Asset Management Plan (省心享 – 華泰 WEFUND 固收私享 FOF1066 號單一資產管理計劃)
Type of product	:	Fixed income
Product risk rating	:	Low-to-medium risk
Principal amount	:	RMB102.0 million
Product subscription date	:	May 14, 2026
Product investment period	:	The product has a term of 10 years. The actual investment period is subject to the exit date of the subscriber.
Expected annualized yield rate	:	The performance will fluctuate with the market and is subject to uncertainty.
Investment scope	:	The proceeds raised under the product will be invested in financial products and cash-type assets.

The principal terms of the HTSC Wealth Management Product Agreement No. 4 are set out as follows:

Name of product	:	Shengxinxiang – Huatai WEFUND Private FOF 1068 Separate Asset Management Plan (省心享 – 華泰 WEFUND 私享 FOF1068 號單一資產管理計劃)
Type of product	:	Mixed
Product risk rating	:	Medium risk
Principal amount	:	RMB216.0 million
Product subscription date	:	May 14, 2026
Product investment period	:	The product has a term of 10 years. The actual investment period is subject to the exit date of the subscriber.
Expected annualized yield rate	:	The performance will fluctuate with the market and is subject to uncertainty.
Investment scope	:	The proceeds raised under the product will be invested in financial products and cash-type assets.

The terms of the HTSC Wealth Management Product Agreements were determined upon arm's length negotiations between the parties.

## **INFORMATION ON THE PARTIES**

The Company is a commercial-ready biopharmaceutical company committed to the discovery, development and commercialization of innovative and differentiated biologics for the treatment of autoimmune, oncology and ophthalmic diseases with unmet medical needs in China and globally.

HTSC is a securities company incorporated in the PRC, the A shares and H shares of which are listed on the Shanghai Stock Exchange (stock code: 601688) and the Stock Exchange (stock code: 06886), respectively. HTSC mainly provides financial services, including wealth management, institutional services, investment management and international business.

To the best knowledge, information and belief of the Directors having made all reasonable enquiries, HTSC and its ultimate substantial beneficial owners as publicly disclosed by HTSC are third parties independent from the Company and its connected persons.

## **REASONS FOR AND BENEFITS OF ENTERING INTO THE HTSC WEALTH MANAGEMENT PRODUCT AGREEMENTS**

On the premise of strictly controlling investment risks, the Company intends to fully revitalize idle funds and improve capital utilization efficiency by deploying and managing idle funds through wealth management products. The allocated low-to-medium risk products feature overall controllable risks and yield higher than those of bank time deposits for the same period, which can effectively boost the investment returns on idle funds.

The Directors consider that the terms of the HTSC Wealth Management Product Agreements and the transactions contemplated thereunder are fair and reasonable, on normal commercial terms or better in the ordinary course of business of the Group, and are in the interests of the Company and its Shareholders as a whole.

## **LISTING RULES IMPLICATIONS**

As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in respect of the HTSC Wealth Management Product Agreements (calculated on an aggregation basis) exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of wealth management products under the HTSC Wealth Management Product Agreements therefore constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the reporting and announcement requirements under the Listing Rules.

## DEFINITIONS

Unless the context otherwise requires, the following terms used herein have the following meanings:

“Board”	the board of Directors
“Company”	RemeGen Co., Ltd.* (榮昌生物製藥(煙台)股份有限公司), a joint stock company incorporated in the PRC with limited liability, the H shares and A shares of which are listed on the Main Board of the Stock Exchange (stock code: 9995) and the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code: 688331), respectively
“connected person”	has the meaning ascribed to it under the Listing Rules
“CSRC”	the China Securities Regulatory Commission
“Director(s)”	the director(s) of the Company
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“HTSC”	Huatai Securities Co., Ltd., a securities company established in the PRC
“HTSC Wealth Management Product Agreements”	the HTSC Wealth Management Product Agreement No. 1, the HTSC Wealth Management Product Agreement No. 2, the HTSC Wealth Management Product Agreement No. 3 and the HTSC Wealth Management Product Agreement No. 4
“HTSC Wealth Management Product Agreement No. 1”	the wealth management product agreement entered into between the Company and HTSC dated May 14, 2026 in relation to the purchase of wealth management product in the amount of RMB60.0 million
“HTSC Wealth Management Product Agreement No. 2”	the wealth management product agreement entered into between the Company and HTSC dated May 14, 2026 in relation to the purchase of wealth management product in the amount of RMB75.0 million
“HTSC Wealth Management Product Agreement No. 3”	the wealth management product agreement entered into between the Company and HTSC dated May 14, 2026 in relation to the purchase of wealth management product in the amount of RMB102.0 million
“HTSC Wealth Management Product Agreement No. 4”	the wealth management product agreement entered into between the Company and HTSC dated May 14, 2026 in relation to the purchase of wealth management product in the amount of RMB216.0 million

“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“PRC” or “China”	the People’s Republic of China excluding, for the purpose of this announcement, Hong Kong, the Macau Special Administrative Region of the People’s Republic of China and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC
“Shareholder(s)”	holder(s) of the shares of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“%”	percent

By order of the Board  
**RemeGen Co., Ltd.\***  
**Mr. Wang Weidong**  
*Chairman and Executive Director*

Yantai, the PRC  
May 14, 2026

*As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian and Mr. Wen Qingkai as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive Directors.*

\* *For identification purpose only*